Member Info for VincentVega

@countingcards

I’m not sure if that was aimed at me, but I bought my first shares in Ciz at over 6.5p in 2021 and have done nothing but average down ever since.

I’d hardly call myself a closet trader.

Also, nobody can ever claim that Ciz is rushing anything, they’re very adept at taking things very slowly.

So it’s back to hibernation until June.

VV

Unfortunately for us the lack of volume today can be directly attributed to AS’s past predictions and broken deadlines.

Potential investors just don’t have faith in his words anymore.

@Bufflehead1992

I suspect that it will be Abbott.

Afterall, they’re currently assisting OmniHealth.

VV..

Basic housekeeping. The least that should be expected.

Where’s the US launch?

10mths late and counting……

I’m thinking they are more likely to be acquired once CLIA approved as should be a material change in both value and opportunity. BIO reckon they are worth $70mn while the UK licence holder is at a mere £5mn, should be easy pickings.

———

That’s another point, entirely. As a starting point of somewhere under 1.5p it would be “easy pickings” to take us out on the cheap.

Not what I’ve waited well over 3 years for.

In summary, I broke my golden rule of never investing in a fledgling bio/pharma company.

More fool me.

Can’t say I blame him/her.

Or it could be that their previous website was just naff!

2 months to go to celebrate CIZ Bio Inc’s 12 month LATE anniversary of their US launch.

Comm’s

As sad as it may seem, I’m hoping that CIZ BIO beat the 12mths late status for the US launch.

A little over 2mths left.

Given the lack of comma’s I won’t hold my breath.

I’d like to know if Lang has a Lien on the IP as part of his ponying up the money in the event of a lowball offer or failure to deliver a functional/marketable final test protocol.

“ Won't take much buying to really propel the SP up towards 2p.......”

Yep, I was expecting just that scenario last year with the much heralded launch date in the US…now 10mths overdue.

Both sides of the trade are recorded in a B&I.

Just as they are in a CFD.

If Ciz can beat my 12mth late for launch in the US by March end.

Frankly, I may need to extend that.

VV

“ Hopefully the former, if the USA branch are in charge of comms.”

I would hope not, given their much trumpeted and clearly very bold prediction of an April 2025 launch.

I’d be surprised if they beat a 12mth late deadline.

VV

I’ve already suggested a potential 2 in a previous, recent post.

I can only see this being bought out for a fraction of its worth.(IP)

How investors never saw this coming after Burrow’s 2024 webcast still shocks me.

I posted the following on here 5th May 2024. I’m now wondering how long it would take a UK partner to get this test through the various regulatory hurdles in order to get this into a live clinical setting, lab or LFT driven…

NHS

AS has chosen the US market to launch the test due to the much narrower timescales in achieving a market ready test via. a LDT accreditation.

Once achieved he is in a much stronger position to approach a partner of the likes of Siemens or Abbott in the task of attaining UKCA accreditation. This would likely involve licensing our tech to enable one of these types of Companies to run the required clinical trials on their proprietary platforms. Such trials are much more defined, time consuming and costly than a LDT. As such, the NHS, whilst an obvious goal, remains secondary to the US trial.

Remember, we’re running with a licensing model here.

IMHO

VV

I’m struggling to see just how you believe that Ciz’s communication has improved.

If only it were that simple.